Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

  • June 2020 •
  • 105 pages •
  • Report ID: 5917302 •
  • Format: PDF
The global non-invasive prenatal testing market is currently witnessing strong growth.

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus. Looking forward, the analyst expects the market to register a CAGR of around 12% during 2020-2025.

Breakup by Product Type:
Consumables
Instruments

Breakup by Test Type:
Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others

Breakup by Technology:
NGS
WGS
Others

Breakup by Test Type:
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others

Breakup by Application:
Trisomy
Microdeletions Syndrome
Others

Breakup by End-User:
Hospitals
Diagnostic Laboratories
Others

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.

Key Questions Answered in This Report:
How has the global non-invasive prenatal testing market performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the test type?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the method?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global non-invasive prenatal testing market and who are the key players?
What is the degree of competition in the industry?